metastatic tumor followed by radiotherapy. Clinically suspected LMM emerged 24 (patient A) and 2 weeks (patient B) after the resection. Patient A experienced radicular pain in both arms. Although MRI scanning revealed LMM, cytology of the first CSF specimen was negative. It was only 4 weeks after this initial investigation, at the second CSF puncture, that malignant cells in the CSF could be detected. Patient B suffered from radicular pain in both legs and diplopia. The clinically suspected LMM initially could not be confirmed by cytological examination of the CSF. After 11 weeks, patient B had developed an organic psychiatric syndrome and multifocal radiculopathy. At that time, a second CSF examination was diagnostic for LMM.
CSF of both patients was collected at the initial clinical presentation of LMM and centrifuged. The pellet was used for cytology, the results of which were negative. Free DNA was isolated from 0.5 mL of the supernatant. A K-ras mutation (codon 12; GGT3 TGT) common for lung adenocarcinoma (4 ) was found for both patients by mutant-allele-specific amplification (MASA; Fig. 1B ) (5, 6 ) . Identical mutations had been found previously in the lung primary (Fig.  1A) and the cerebellum metastasis. Other K-ras mutations were absent.
In controls, including two patients with LMM without a K-ras mutation in the tumor and three patients with nonneoplastic disease (multiple sclerosis, meningitis, and Alzheimer disease), no mutant K-ras could be detected in the CSF supernatant.
We conclude that detection of Kras mutations in the CSF of clinically suspected LMM patients is a promising tool for early diagnosis, followup, and treatment monitoring of LMM derived from primary adenocarcinoma of the lung. Moreover, with sensitive methods such as MASA, it is relatively easy to screen for K-ras point mutations in the CSF supernatant, which is not used for cytology, even without previous knowledge of the tumor mutations.
Because K-ras mutations are found in only 30% of the adenocarcinoma of the lung (4 ) and are rare in other solid tumors that frequently metastasize to the leptomeninges (7 ), additional molecular markers for the management of LMM are of potential interest (8, 9 (2, 4 ) ; the test method was run on an Hitachi 911 analyzer (Boehringer Mannheim/Roche). A split-sample comparison was done with six specimens covering the HDL-C concentration range. All specimens were from individual donors. The matrix types investigated with the test method were serum and heparin plasma, whereas serum was used in combination with the DCM. Fresh specimens, intermittently stored at 4°C, were analyzed with the test method, whereas frozen split sera were analyzed with the HDL-C DCM (5, 6 ) . With the test method, all specimens were run in duplicate during 3 consecutive days for a total of 36 measurements (6 ϫ 3 ϫ 2 measurements); with the DCM, duplicate analyses were performed in one analytical run for a total of 12 measurements (6 ϫ 2 measurements). Both test and reference data were produced in the Clinical Chemistry 46, No. 1, 2000 Lipid Reference Laboratory in Rotterdam. Analytical performance was checked against the National Cholesterol Education Program guidelines (4 ) . New lot combinations were acceptable when the total error criterion of 13% was met. Total error can be considered as an error budget that can be divided between imprecision and bias (4, 7) .
During a 2-year period, 31 reagent/calibrator lot combinations for direct HDL-C were evaluated. For serum, the mean (Ϯ SD) results were as follows: mean bias (%), Ϫ1.6% Ϯ 3.0%; mean absolute bias (%), 3.0% Ϯ 1.9%; overall imprecision, 1.5% Ϯ 0.7%; and total error, 5.5% Ϯ 2.5%. For heparin plasma, the mean (Ϯ SD) results were as follows: mean bias (%), Ϫ2.7% Ϯ 3.1%; mean absolute bias (%), 3.8% Ϯ 2.1%; overall imprecision, 1.6% Ϯ 0.7%; and total error, 6.2% Ϯ 2.7%. In four reagent/calibrator lot combinations, the mean bias exceeded Ϯ 5%, i.e., the excessive bias was related to one specific lot of calibrator in three combinations and to a specific reagent lot only once. In none of the combinations did the total error exceed 13%, the maximum total error being 11.1% for one serum matrix and 12.1% for the corresponding heparin plasma. Hence, all tested combinations were sold on the Dutch market. In the HDL-C reagent kit, a "Document of Comparison" issued by the Lipid Reference Laboratory Rotterdam is inserted, stating the overall analytical CV (%), the percentage of bias, and the percentage of total error for both matrices and for the tested reagent/calibrator lot numbers on a Hitachi 911 system.
It is concluded that the lot-to-lot differences of the direct HDL-C reagent and calibrator during the past 2 years were acceptable and in agreement with the 1998 National Cholesterol Education Program recommendations for HDL-C method performance (4 ). We have been assured that Roche will make further efforts to decrease the method bias to less than Ϯ 5% in all combinations. The inserted Document of Comparison with the stated method bias and total error is objective evidence that should aid clinical chemists in the field to judge whether the quality of different lots of direct HDL-C reagent and calibrator meets recommended standards (4 ) . In general, the results obtained for analytical performance characteristics should be compared to well-documented, objective quality specifications. We believe that assessment of the analytical performance by independent bodies across different sales lots should become part of (inter)national reagent release.
